ПОКАЗНИКИ НЕСПЕЦИФІЧНОГО СИСТЕМНОГО ЗАПАЛЕННЯ ЯК КРИТЕРІЇ ДЕСТАБІЛІЗАЦІЇ ПЕРЕБІГУ ІШЕМІЧНОЇ ХВОРОБИ СЕРЦЯ

Автор(и):

Ключові слова:

ішемічна хвороба серця неспецифічне системне запалення високочутливий С-реактивний протеїн фактор некрозу пухлин-α

Посилання:

1. Antomonov MYu. Matematicheskaya obrabotka i analiz mediko-biologicheskikh dannykh. Kií̈v: Maliy druk; 2006. 558 s [in Russian]
2. Kovalenko VM, Kornatskyy VM, editors. Aktualni problemy zdorovya ta minimizatsiya yikh v umovakh zbroynoho konfliktu v Ukrayini: posibnyk. Kyiv: Derzhavna ustanova “Natsionalnyy naukovyy tsentr “Instytut kardiolohiyi imeni akademika M.D.Strazheska”; 2018. 518. [in Ukrainian]
3. Romanova VO, Kuzminova NV, Sierkova VK, Romanova LO, vynakhidnyky; Vinnytskyy natsionalnyy medychnyy universytet im. M.I.Pyrohova, patentovlasnyk. Sposib vyznachennya destabilizatsiyi perebihu zakhvoryuvannya u patsiyentiv z ishemichnoyu khvoroboyu sertsya. Patent Ukainy No. 127360. 2018 Lyp 25. [in Ukrainian]
4. Fedotova LA, Zorin VN, Plastun MYu. Gemostaz, fibrinoliz pri ishemicheskoy bolezni serdtsa i arterial'noy gipertenzii. Tavricheskiy mediko-biologicheskiy vestnik. 2013;4(64):183–186 [in Russian]
5. Cui Z, Zhao G, Liu X. Blood fibrinogen level as a biomarker of adverse outcomes in patients with coronary artery disease: A systematic review and meta-analysis. Medicine. 2022;101(33). DOI: 10.1097/md.0000000000030117
6. De Caterina R, D’Ugo E, Libby P. Inflammation and thrombosis – testing the hypothesis with anti- inflammatory drug trials. Thrombosis and Haemostasis. 2016;116(12):1012–21. DOI 10.1160/th16-03-0246
7. Ivanytskyi IV, Katerenchuk OI, Nekrasov KA, Ivanytska TA. Left ventricular noncompaction associated with genetic disturbance of folic acid metabolism. Kardiol Pol. 2019;77(12):1196–1197. DOI: 10.33963/KP.15024
8. Kuzminova N, Romanova V, Serkova V, Osovska N, Kniazkova I. Inflammation indicators and leptin level in patients with ischemic heart disease. Lekarsky Obzor. 2016;65(6):140–5.
9. Liberale L, Ministrini S, Carbone F, Camici GG, Montecucco F. Cytokines as therapeutic targets for cardio- and cerebrovascular diseases. Basic Research in Cardiology. 2021;116(1). DOI: 10.1007/s00395-021-00863-x
10. Omran F, Kyrou I, Osman F, Lim V, Randeva H, Chatha K. Cardiovascular biomarkers: Lessons of the past and prospects for the future. International Journal of Molecular Sciences. 2022;23(10):5680. DOI: 10.3390/ijms23105680
11. Ridker PM. Residual inflammatory risk: Addressing the obverse side of the Atherosclerosis Prevention Coin. European Heart Journal. 2016;37(22):1720–2. DOI 10.1093/eurheartj/ehw024
12. Schroder J, Mygind ND, Frestad D, Michelsen M, Suhrs HE, Bove KB, et al. Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction. IJC Heart & Vasculature. 2019;24:100370. DOI: 10.1016/j.ijcha.2019.100370
13. Townsend N, Kazakiewicz D, Lucy Wright F, Timmis A, Huculeci R, Torbica A, et al. Epidemiology of Cardiovascular Disease in Europe. Nature Reviews Cardiology. 2021;19(2):133–43. DOI: 10.1038/s41569-021-00607-3
14. Urschel K, Cicha I. TNF-Α in the cardiovascular system: From physiology to therapy. International Journal of Interferon, Cytokine and Mediator Research. 2015;7:9–25. DOI: 10.2147/ijicmr.s64894
15. Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circulation Research. 2019;124(2):315–27. DOI: 10.1161/circresaha.118.313591

Публікація:

«Світ медицини та біології» Том 18 № 82 (2022) , с. 153-157
УДК 616.13-002:616.12-005.4-08

DOI:

https://doi.org/10.26724/2079-8334-2022-4-82-153-157